Author:
Willemsen Annelieke E.C.A.B.,He Xuehui,van Cranenbroek Bram,de Jong Paul C.,de Boer Maaike,Joosten Irma,Koenen Hans J.P.M.,van Herpen Carla M.L.,Gerritsen Winald R.
Subject
Pharmacology,Immunology,Immunology and Allergy
Reference40 articles.
1. Current development of mTOR inhibitors as anticancer agents;Faivre;Nat. Rev. Drug. Discov.,2006
2. Rapamycin: something old, something new, sometimes borrowed and now renewed;Hartford;Clin. Pharmacol. Ther.,2007
3. Targeting the mammalian target of rapamycin (mTOR) in cancer therapy: lessons from past and future perspectives;Dufour;Cancers (Basel),2011
4. Everolimus, Highlights of prescribing information. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022334s040,203985s013lbl.pdf (accessed: 27th October 2019).
5. Regulation and function of mTOR signalling in T cell fate decisions;Chi;Nat. Rev. Immunol.,2012
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献